Immature Neurons Linked to Alzheimer’s Resilience TL;DR: A 2026 Cell Stem Cell study used single-nucleus RNA sequencing of aged human hippocampus tissue and found rare immature neurons in healthy, Alzheimer’s, and dementia-resilient brains. The important signal was not simply whether these cells existed. It was how their gene activity changed in Alzheimer’s disease and in …
Early Locus Coeruleus Axon Loss May Explain Smell Loss in Alzheimer’s TL;DR: Alzheimer’s-model mice lost noradrenergic locus coeruleus axons in the olfactory bulb before major plaque buildup, took 60% longer to find buried food, and improved when microglial phagocytosis was reduced. Key Findings 3-month axon loss before heavy plaque load: AppNL-G-F mice showed a selective …
SuperAgers Reveal Brain Biology of Preserved Memory TL;DR: Octogenarians who recall words like 50-year-olds carry a distinct brain profile: preserved cortical volume, a cingulate cortex thicker than younger adults, larger entorhinal neurons, fewer inflammatory microglia, and more von Economo neurons — the biology is real, not just motivational. Key Findings Age-80 memory matched 50-to-60-year-olds: SuperAgers …
Lifetime Cognitive Enrichment Delayed Alzheimer’s Dementia TL;DR: In 1,939 Rush Memory and Aging Project participants, higher lifetime cognitive enrichment was linked to 38% lower Alzheimer’s dementia hazard and about 5 years later dementia onset. Key Findings 1,939 dementia-free adults: Participants were older adults from Northeastern Illinois in the Rush Memory and Aging Project, with a …
Dopamine Disruption May Start Alzheimer’s Memory Failure TL;DR: In an Alzheimer’s mouse model, early memory failure tracked a broken dopamine signal into the lateral entorhinal cortex, and both optogenetic dopamine reactivation and L-DOPA partially restored learning. Key Findings Early learning slipped: Young APP knock-in mice reached 78.6% correct trials in the final learning block, compared …
Alzheimer’s Treatment Needs More Than Amyloid TL;DR: A 2026 review in Science China Life Sciences argues that amyloid-beta antibodies such as lecanemab and donanemab are important progress, but Alzheimer’s treatment cannot stop at amyloid. The disease also involves tau tangles, genetics, aging biology, immune changes, vascular and metabolic health, and systemic conditions that shape whether …
Alpha-Synuclein Testing Could Clarify Dementia Diagnosis TL;DR: In 398 memory-clinic patients, alpha-synuclein seed testing identified Lewy body dementia with 95% sensitivity and revealed hidden synuclein positivity in 15.8% of Alzheimer’s disease cases. Key Findings Seed testing separated Lewy body dementia: The ALZAN cohort recruited memory-clinic patients from Montpellier, Nimes, and Perpignan between November 2022 and …
Caffeinated Coffee Linked to Lower Dementia Risk Over 43 Years TL;DR: Caffeinated coffee drinkers had 141 vs 330 dementia cases per 100,000 person-years in the highest versus lowest intake quartiles — across 131,821 adults followed up to 43 years. Decaf showed no comparable signal. Key Findings Caffeinated coffee: 141 vs 330 dementia cases per 100,000 …
Broken Blood Vessels May Drive Alzheimer’s Decline TL;DR: A new study reveals that impaired cerebrovascular function—the brain’s ability to regulate blood flow—correlates strongly with Alzheimer’s symptoms, offering a potential non-invasive way to detect early cognitive decline. Alzheimer’s disease has long been framed as a problem of toxic protein accumulation: amyloid plaques and tau tangles strangling …
How Lecanemab Clears Brain Amyloid: The Microglia Key TL;DR: Lecanemab, the first Alzheimer’s antibody to slow cognitive decline, works by activating immune cells called microglia through a specific immune signaling pathway, with the molecule SPP1/osteopontin playing a critical role in triggering the brain’s own cleanup machinery. When lecanemab was approved by the FDA, it sparked …
